Blood, 2022-11, Vol.140 (Supplement 1), p.9443-9445
- Phillips, Tycel
- Thieblemont, Catherine
- Ghesquieres, Herve
- Cheah, Chan Y.
- Clausen, Michael Roost
- Cunningham, David
- Do, Young Rok
- Feldman, Tatyana A.
- Gasiorowski, Robin
- Jurczak, Wojciech
- Kim, Tae Min
- Lewis, David John
- van der Poel, Marjolein
- Poon, Michelle Limei
- Kilavuz, Nurgul
- Cota Stirner, Mariana
- Soong, David
- Chiu, Christopher
- Chen, Menghui
- Sacchi, Mariana
- Elliot, Brian
- Hutchings, Martin
- Lugtenburg, Pieternella
2022
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Phillips, Tycel
- Thieblemont, Catherine
- Ghesquieres, Herve
- Cheah, Chan Y.
- Clausen, Michael Roost
- Cunningham, David
- Do, Young Rok
- Feldman, Tatyana A.
- Gasiorowski, Robin
- Jurczak, Wojciech
- Kim, Tae Min
- Lewis, David John
- van der Poel, Marjolein
- Poon, Michelle Limei
- Kilavuz, Nurgul
- Cota Stirner, Mariana
- Soong, David
- Chiu, Christopher
- Chen, Menghui
- Sacchi, Mariana
- Elliot, Brian
- Hutchings, Martin
- Lugtenburg, Pieternella
- Titel
- Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
- Ist Teil von
- Blood, 2022-11, Vol.140 (Supplement 1), p.9443-9445
- Ort / Verlag
- Elsevier Inc
- Erscheinungsjahr
- 2022
- Quelle
- Alma/SFX Local Collection
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0006-4971eISSN: 1528-0020DOI: 10.1182/blood-2022-158245Titel-ID: cdi_crossref_primary_10_1182_blood_2022_158245
- Format
- –